ABSTRACT
SUMMARY OBJECTIVE: This study aimed to explore and analyze the therapeutic effect of the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG on underweight and malabsorption in premature infants. METHODS: This is a retrospective study. The clinical data of 68 premature infants admitted to Beijing United Family Hospital (Private Secondary Comprehensive Hospital, Chaoyang District, Beijing, China) from January 2016 to January 2022 were analyzed retrospectively. Preterm infants less than 37 weeks of gestational age admitted to the neonatal intensive care unit were included in the study. Patients with intestinal malformations, necrotizing enterocolitis, etc., who require long-term fasting were excluded. A telephone follow-up was performed 3-6 months after discharge. They were classified as treatment groups A and B according to the treatment plan. The treatment group A included parenteral nutrition, enteral nutrition, etc. In treatment group B, based on treatment group A, the premature infants were treated with Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG. The time to regain birthweight and the weight on day 30 were compared between the two groups, as was the duration of transition from parenteral nutrition to total enteral nutrition. RESULTS: The time of weight regain birthweight in group B was shorter than that in group A (t=-2.560; t=-4.287; p<0.05). The increase of weight on day 30 in group B was significantly higher than that in group A (t=2.591; t=2.651; p<0.05). The time from parenteral nutrition to total enteral nutrition in group B was shorter than that in group A (z=-2.145; z=-2.236; p<0.05). CONCLUSION: In the treatment of premature infants, the combination of Bifidobacterium animalis subsp. lactis BB-12® and Lactobacillus rhamnosus GG can have a better therapeutic effect on the underweight and malabsorption of premature infants, and this treatment method can be popularized in clinics.
ABSTRACT
Introduction:Aprobiotic used as an adjunct in Salmonella typhi infection along with antibiotic is postulated to interfere with the virulence and growth of Salmonella. To determine the effectiveness of Lactobacillus rhamnosusGG (LGG), as an adjunct with intravenous ceftriaxone, compared with a placebo in defervescence and toxemia resolution in children with enteric fever. Settings and Design: This hospital‑based randomized double‑blinded controlled trial was conducted among 56 study participants who were children below the age of 12 years, admitted as inpatients with fever and whose blood culture grew S. typhi. Materials and Methods: Study participants were equally allocated into intervention or control group by simple randomization. The intervention group received injection ceftriaxone and oral LGG (probiotic) for 7 days while the control group received an injection ceftriaxone and oral placebo for 7 days. Statistical Analysis: Kaplan–Meier curves and mantel cox log‑rank test were used to compare the duration for defervescence and toxemia resolution after treatment initiation. Results: Mean duration for defervescence in the intervention and control groups was 3.87 (1.57) days and 3.35 (1.19) days, respectively. The mean time taken for the resolution of toxemia was 3.00 (1.15) days in the intervention group and 2.64 (0.87) days in the control group. Conclusions:The addition of oral LGG at a dose of 3 × 109 colony‑forming units for 7 days to the standard antibiotic therapy for enteric fever did not show a significant reduction in the time taken for defervescence (P = 0.099) or resolution of toxemia (P = 0.148)
ABSTRACT
Intestinal microbiota is the most complex and important microecosystem in the human body， and gut microbiota dysbiosis is closely associated with the development and progression of acute pancreatitis. Targeted regulation of intestinal microecology in assisting the treatment of acute pancreatitis has attracted more attention in recent years. This article describes the changes in intestinal microbiota and related mechanisms in patients with acute pancreatitis， summarizes the current research status of the use of probiotics， points out the research direction of probiotics as the adjuvant treatment regime， and proposes a new method for predicting the dominant flora in patients with acute pancreatitis， in order to bring new ideas for the treatment of acute pancreatitis.
ABSTRACT
El parto prematuro, las cesáreas, los antibióticos y la lactancia materna limitada contribuyen al aumento de enfermedades crónicas no transmisibles. El objetivo fue realizar una revisión descriptiva del uso de probióticos en pediatría, con foco en la cepa Lactobacillus rhamnosus GG. Ciertos probióticos han demostrado ser eficaces en la diarrea aguda y en la diarrea asociada a antibióticos. L. rhamnosus GG y Saccharomyces boulardii pueden acortar la duración y los síntomas. L. reuteri DSM 17938 y L. rhamnosus GG fueron efectivos para el abordaje del cólico del lactante. El uso de esta cepa en fórmulas infantiles para alergia a las proteínas de leche de vaca promovería la adquisición más temprana de tolerancia. En la prevención de dermatitis atópica, la administración de L. rhamnosus GG durante el embarazo redujo su manifestación en el bebé. El empleo de probióticos como coadyuvantes es una posibilidad para considerar en la práctica pediátrica actual.
Preterm birth, C-sections, antibiotics, and limited breastfeeding contribute to the increase in noncommunicable diseases. Our objective was to perform a descriptive review of probiotic use in pediatrics, focused on Lactobacillus rhamnosus GG. Certain probiotics have demonstrated to be effective in acute diarrhea and antibiotic-associated diarrhea. L. rhamnosus GG and Saccharomyces boulardii may shorten their duration and symptoms. L. reuteri DSM 17938 and L. rhamnosus GG were effective to manage infant colic. The use of this strain in infant formulas for cow's milk protein allergy may promote an earlier tolerance acquisition. In relation to the prevention of atopic dermatitis, the administration of L. rhamnosus GG during pregnancy reduced its development in the infant. The use of probiotics as adjuvants is a possibility to consider in current pediatric practice.
Subject(s)
Humans , Infant, Newborn , Pediatrics , Milk Hypersensitivity , Probiotics/therapeutic use , Premature Birth , Lacticaseibacillus rhamnosus , Cattle , Epidemiology, DescriptiveABSTRACT
Objective:To study the protective effect of alendronate combined with Lactobacillus rhamnosus on bone loss in ovariectomized mice.Methods:Fifty female C57BL/6 mice were divided into 5 equal groups ( n=10). Ovariotomy was performed in groups A, B, C and D while a sham operation was performed in group E. Group A was subjected to combined administration of alendronate and Lactobacillus rhamnosus, group B to administration of alendronate, group C to administration of Lactobacillus rhamnosus, and groups D and E to administration of physiological saline only. At 3 months after operation, all the mice were sacrificed to harvest their femurs. Micro CT scanning was performed to detect the bone mineral density (BMD), trabecular relative volume, bone surface area/bone volume, and trabecular thickness and number of trabecular bone. Three-point bending test was used to detect the maximum load, stiffness, ultimate load, Young＇s modulus, and fracture energy. Osteocalcin and alkaline phosphatase levels were measured using blood samples from the mice eyeballs. The 2 groups were compared in terms of all the above indexes. Results:The BMD [(669.87±67.87) mg/cm 3], maximum load [(14.35±0.75) N] and fracture energy [(1,497.43±38.29) J/m 2] in group A were significantly higher than those in group B [(520.07±9.01) mg/cm 3, (11.94±0.82) N and(1,277.61±35.12) J/m 2] and group C [(388.15±25.61) mg/cm 3, (11.10±0.93) N and (1,115.27±63.24) J/m 2] (all P<0.05). The osteocalcin level in group A [(22.25±1.78) ng/mL] was significantly higher than that in group B [(19.08±1.45) ng/mL] and group D [(19.33±1.66) ng/mL] (both P<0.05). The alkaline phosphatase level in group A [(83.21±9.69) ng/mL] was significantly lower than that in group C [(113.16±14.44) ng/mL] and group D [(137.96±14.01) g/mL] (both P<0.05). Conclusion:Alendronate combined with Lactobacillus rhamnosus may play a synergistic role in prevention of bone loss in ovariectomized mice, because combined administration of the two is more effective than administration of either of the two.
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD)has become one of the most common chronic liver diseases in children, which has a wide spectrum including the nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis and hepatocellular carcinoma (HCC)with its clinical consequences.At least 50% of obese children present NAFLD.Increased levels of free fatty acids and insulin resistance play major roles in NAFLD progression, resulting in excessive accumulation of triglycerides in hepatocytes.Lactobacillus rhamnoides is one of the most thoroughly studied intestinal probiotics, and its role in NAFLD progress has been growingly concerned.Lactobacillus rhamnosus GG alleviates NAFLD in children by improving intestinal microbiota dysbiosis, increasing intestinal barrier integrity, promoting fatty acid β-oxidation, and reducing hepatic triglyceride accumulation via regulating bile acid metabolism.Recent studies have shown that microRNAs are involved in multiple pathways to alleviate NAFLD-associated lipid metabolism disorders, which are functional as noninvasive diagnostic marker of fatty liver disease in children.This review mainly summarizes that Lactobacillus rhamnosus GG improves NAFLD in children from multiple metabolic pathways, aiming to provide a new strategy and target for the treatment and early diagnosis of NAFLD in children.
ABSTRACT
Intestinal microorganisms are closely related to human health or disease status. Spinal cord injury is a serious traumatic disease of the nervous system. Recent studies have shown that intestinal flora can affect the progression of spinal cord injury. At the same time, intestinal flora is closely related to spinal cord injury complications such as anxiety, depression, aspiration pneumonia, malnutrition, constipation, neurocystitis and urinary system infection through intestinal-brain axis, intestinal-lung axis and oral-pulmonary axis. In this paper, the intestinal flora will be used as the starting point to explore the relationship between spinal cord injury, intestinal flora and spinal cord injury complications, providing new ideas for the treatment of spinal cord injury patients and the prevention of complications.
ABSTRACT
Intestinal flora imbalance plays a certain role in the development and progression of liver cancer, while probiotics have a certain impact on liver cancer, both of which are the focus of clinical research. This article introduces the mechanism of action of intestinal flora imbalance in the pathogenesis of liver cancer and the preventive effect of probiotics against liver cancer. Intestinal flora imbalance can participate in the pathological process of liver cancer by activating Toll-like receptor 4, regulating the level of metabolites, producing endotoxin, and inducing bacterial translocation and intestinal bacterial overgrowth, while probiotics can effectively prevent liver cancer by maintaining enterohepatic circulation, enhancing immune function, promoting the reproduction of intestinal probiotics, and reducing the toxicity of carcinogens, which can be further studied as the focus of subsequent liver cancer prevention in clinical practice.
ABSTRACT
Aims@#Probiotics are claimed to confer many health effects upon consumption. However, the survivability of probiotic under the harsh conditions in the gastrointestinal tract has been a challenge. This study aimed to improve the survivability of Lactobacillus rhamnosus GG under gastrointestinal condition through co-extrusion microencapsulation and the addition of black bean extract. @*Methodology and results@#Optimization was carried out on wall material formulation, types of pectin (low and high methoxyl pectin) and alginate: pectin ratio (2:1 and 3:1), and black bean extract concentration (0 to 1% w/v) to produce capsules with desired properties. The effect of L. rhamnosus GG microencapsulation with and without black bean extract on its survivability under simulated gastrointestinal conditions was also investigated. The optimal formulation that gives the highest microencapsulation efficiency (86.17%) was low methoxyl pectin, alginate: pectin ratio at 3:1, and 0.5% (w/v) of black bean extract. The inclusion of black bean extract into L. rhamnosus GG microencapsulation showed no significant effect (p >0.05) on the capsule diameter, with a mean diameter of 715.44 µm and a high microencapsulation efficiency of 97.4%. The viability of encapsulated L. rhamnosus GG increased with black bean extract after 6 h of sequential digestion with the final viable cell count of 12.47 log10 CFU/mL, which meet the minimum requirement of 10
Subject(s)
Lacticaseibacillus rhamnosus , Alginates , PhaseolusABSTRACT
6 years (RR=4.15), with previous abdominal pain (RR=7.2) or constipation (RR=4.06). Constipation was recorded in 23/289 (8.0%), with increased risk in children having surgery (RR=2.56) or previous constipation (RR=7.38). Probiotic supplementation significantly reduced AAD (RR=0.30) and abdominal pain (RR=0.36). Lactobacillus rhamnosus GG (LGG) and L. reuteri significantly reduced AAD (RR=0.37 and 0.35) and abdominal pain (RR=0.37 and 0.24).CONCLUSION: AAD occurred in 20.4% of children, with increased risk at younger age, lower respiratory and urinary tract infections, intravenous treatment and previous AAD. LGG and L. reuteri reduced both AAD and associated abdominal pain.
Subject(s)
Child , Humans , Abdominal Pain , Administration, Intravenous , Anti-Bacterial Agents , Constipation , Diarrhea , Incidence , Inpatients , Limosilactobacillus reuteri , Lacticaseibacillus rhamnosus , Probiotics , Prospective Studies , Protective Factors , Urinary Tract InfectionsABSTRACT
Background: Diarrhoea is the second most common cause of under-five mortality especially in developing world. Many studies have been conducted so far using different probiotic strains with variable outcome. So, the aim of the present study was to compare the clinical efficacy of Bacillus clausii and multi strain probiotic formulation as adjunct treatment of acute diarrhoea.Methods: This prospective single blind randomized controlled clinical trial included 300 infants and children between 6 months to 6 years of age admitted in a tertiary care hospital Sylhet, Bangladesh with acute watery diarrhoea having varied dehydration status ranging from no to severe dehydration excluding shocked state. Cases were randomly assigned to three groups which were group I (n=100) comprised of children who were treated with standard treatment (according to WHO guideline) only as control group, group II (n=100) who received standard treatment plus Bacillus clausii and group III (n=100) who received standard treatment plus multi strain probiotic formulation (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophilus). Primary outcome variables were duration, frequency of diarrhoea and consistency of stool. Secondary outcome variable was duration of hospital stay.Results: Mean duration of diarrhoea was significantly shorter (p=0.001) in group III (2.62 days) compared to group I (3.26 days) and group II (3.22 days). Frequency of diarrhoea was significantly lower on day 3 of probiotic administration in group III (p <0.05) and on day 5 of treatment in group II (p <0.05). Stool consistency significantly improved on day 3 in group III (p <0.05) while it was on day 4 in group II. The duration of diarrhoea, hospital stay, stool consistency and frequency of stool on day 3 were not statistically significant (p >0.05) in group II in comparison to group I and group III.Conclusions: Multistrain probiotic formulation is effective in reducing the duration, frequency of diarrhoea and duration of hospital stay.
ABSTRACT
To understand the effects of Lactobacillus rhamnosus GG (ATCC 53103) on intestinal barrier function in pre-weaning piglets under normal conditions, twenty-four newborn littermate piglets were randomly divided into two groups. Piglets in the control group were orally administered with 2 mL 0.1 g/mL sterilized skim milk while the treatment group was administered the same volume of sterilized skim milk with the addition of viable L. rhamnosus at the 1st, 3rd, and 5th days after birth. The feeding trial was conducted for 25 d. Results showed that piglets in the L. rhamnosus group exhibited increased weaning weight and average daily weight gain, whereas diarrhea incidence was decreased. The bacterial abundance and composition of cecal contents, especially Firmicutes, Bacteroidetes, and Fusobacteria, were altered by probiotic treatment. In addition, L. rhamnosus increased the jejunal permeability and promoted the immunologic barrier through regulating antimicrobial peptides, cytokines, and chemokines via Toll-like receptors. Our findings indicate that oral administration of L. rhamnosus GG to newborn piglets is beneficial for intestinal health of pre-weaning piglets by improving the biological, physical, and immunologic barriers of intestinal mucosa.
ABSTRACT
Objective To investigate the effects of Lactobacillus rhamnosus GG (LGG) colonization in early life on intestinal barrier and intestinal development in offspring mice and its possible mechanism.Methods Six C57BL/6 pregnant mice with the same conception time of 6 weeks were selected and randomly divided into experiment group given 108 cfu/ml LGG live bacteria and control group given LGG inactivated bacteria by gavage from the 18th day of pregnancy until natural birth.The progeny mice in the two groups were continued to be gavaged with 107 cfu/ml of LGG live bacteria or LGG inactivated bacteria on days 1-5 of birth.The body weight changes of 3 week'progeny mice were recorded.The colonization of LGG bacteria in offspring mice was detected at 2nd and 3rd weeks.The mRNA of intestinal proinflammatory cytokines and tight junction molecules were evaluated by real-time PCR method.HE,immunohistochemistry,immunofluorescence staining and enzyme-linked immunosorbent assay were used to evaluate the intestinal barrier of 3-week old off spring mice.Results Compared with the control group,the progeny mice of the experiment group showed no significant difference in body weight at the first week,and the body weight increased at the second week and the third week [2ndweek:(3.790±0.240) g vs.(4.326±0.140) g,t=3.707,P=0.006;3rd week:(7.295±0.326) g vs.(8.040±0.370) g,t=3.130,P=0.011].LGG colonization can be detected only in the feces of progeny mice in the experiment group.Intestinal colonization can promote the growth of small intestine villi and colon crypt depth [jejunum:(320.000±22.514) μm vs.(265.100±15.611) μm,t=8.258,P＜0.001;ileum:(150.500±13.099) μm vs.(111.000±11.308) μm,t=9.958,P＜0.001;colon:(295.000±15.209) μm vs.(233.100±6.678) μm,t=9.129,P＜0.001].Compared with the control group,the number of goblet cells in the colonic crypt of the experiment group increased (11.62 ± 0.780 vs.35.24 ±1.370,t=15.000,P＜0.001),and the relative mRNA expression levels of pro-inflammatory factors as IFN-γ (1.280±0.232 vs.0.512±0.206,t=4.970,P=0.001),IL-6 (1.364±0.271 vs.0.941±0.215,t=2.452,P=0.040),IL-10 (1.341±0.320vs.0.744±0.294,t=2.762,P=0.025)andTNF-α (3.702±0.150 vs.2.581±0.500,t=2.553,P=0.034) in the experiment group decreased;the expression levels of the intimate tight junction molecules (Claudin3) (1.283±0.152 vs.1.881±0.172,t=4.932,P=0.001) and the atresia protein molecule (Occludin) (1.164±0.342 vs.0.812±0.224,t=3.67,P=0.016) significantly increased.Conclusion Early life LGG colonization protects the intestinal barrier by inhibiting lowgrade intestinal inflammation.This study will lay the experimental foundation for the supplementation of probiotics in early life so as to prevent intestinal diseases.
ABSTRACT
ABSTRACT BACKGROUND: Helicobacter pylori (H. pylori) has been introduced by since 1983 by Marshal and Warren to play the main role in the pathophysiology of gastritis and gastric ulcers. Almost half of the world population1 is infected by H. pylori. Current therapeutic regimen against H. pylori includes the use of a proton pump inhibitor plus two or more antibiotics. However, the efficacy of this regimen is decreasing mainly due to antibiotic resistance and side effects of medications. This fact has resulted in public interest in other therapeutic options and the role of probiotics merits special attention in this regard. OBJECTIVE: This study aims to evaluate the efficacy of honey-derived Lactobacillus rhamnosus on H. pylori-induced gastric inflammation and gastro-intestinal infection in C57BL/6 Mice. METHODS: The 24 C57BL/6 Mice were randomly divided into three groups of eight mice each. All the mice were fed with 1cc suspension containing 5*1010 CFU/ mL of ATCC43504 strains of H. pylori for 3 consecutive days, twice daily via polyethylene gavage tubes. At the end of 4th week, infection with H. pylori was confirmed with stool Ag (ELISA) and following sacrifice of one mouse from each group, histopathologic study confirmed gastritis. The groups were subjected to different therapies as stated, 1: without Bismuth (Bi), Omeprazole (Om) and L. rhamnosus prescription, 2: Bi, Om and Clarithromycin (Cl) and 3: Bi, Om plus 1cc of suspension of 109 CFU/mL of L. rhamnosus. After 2 weeks, the stool was analyzed for Ag and the mice were sacrificed for evaluation of histopathologic changes. RESULTS: Treatment with L. rhamnosus group provided Zero titer of stool Ag and was associated with improved gastric inflammation in all subjects, similar to the clarithromycin group. CONCLUSION: Honey-derived L. rhamnosus probiotics provides similar results as clarithromycin in terms of improvement of H. pylori infection and gastritis in C57BL/6 Mice model, without its cons of antibiotic resistance.
RESUMO CONTEXTO: O Helicobacter pylori (H. pylori) foi reconhecido em 1983 por Marechal e Warren como protagonista principal na fisiopatologia de gastrite e úlceras gástricas. Quase metade da população mundial está infectada por H. pylori. O regime terapêutico atual contra H. pylori inclui o uso de um inibidor da bomba de prótons associada a dois ou mais antibióticos. No entanto, a eficácia deste regime está diminuindo principalmente devido à resistência aos antibióticos e efeitos colaterais de medicamentos. Este fato resultou no interesse público em outras opções terapêuticas e o papel dos probióticos merece atenção especial a este respeito. OBJETIVO: Este estudo visa avaliar a eficácia do mel-derivado do Lactobacillus rhamnosus na inflamação gástrica e infecção gastrointestinal H. pylori-induzida em camundongos C57Bl/6. MÉTODOS: Vinte e quatro camundongos C57Bl/6 foram divididos aleatoriamente em três grupos de oito camundongos cada. Todos os ratos foram alimentados com suspensão de 1cc contendo 5*1010 UFC/mL de cepas ATCC43504 de H. pylori por 3 dias consecutivos, duas vezes por dia através de gavagem por tubos de polietileno. No final da 4ª semana, a infecção com H. pylori foi confirmada pelo antígeno fecal (ELISA) e após o sacrifício de um rato de cada grupo, o estudo histopatológico confirmou gastrite. Os grupos foram submetidos a diferentes terapias, como indicado, 1: sem prescrição de bismuto (BI), Omeprazol (Om) e L. rhamnosus, 2: Bi, Om e claritromicina (CL) e 3: Bi, Om mais 1cc de suspensão de 109 UFC/mL de L. rhamnosus. Após 2 semanas, as fezes foram analisadas para o antígeno e os ratos foram sacrificados para a avaliação das alterações histopatológicas. RESULTADOS: O tratamento com o grupo L. rhamnosus forneceu o título zero de antígeno e foi associado com a inflamação gástrica melhorada em todos os camundongos, similar ao grupo claritromicina. CONCLUSÃO: O probiótico mel-derivado L. rhamnosus fornece resultados semelhantes ao da claritromicina em termos de melhoria da infecção H. pylori e gastrite em C57Bl/6 camundongos modelos, sem os inconvenientes de resistência aos antibióticos.
Subject(s)
Animals , Male , Helicobacter pylori , Helicobacter Infections/therapy , Probiotics/therapeutic use , Lacticaseibacillus rhamnosus , Gastritis/therapy , Honey/microbiology , Time Factors , Enzyme-Linked Immunosorbent Assay , Colony Count, Microbial , Random Allocation , Reproducibility of Results , Helicobacter Infections/microbiology , Treatment Outcome , Clarithromycin/pharmacology , Disease Models, Animal , Gastric Mucosa/microbiology , Gastric Mucosa/pathology , Gastritis/microbiology , Mice, Inbred C57BL , Anti-Bacterial Agents/pharmacologyABSTRACT
Bebidas de origem vegetal vêm sendo estudadas como carreadoras de bactérias probióticas. Neste estudo objetivou-se elaborar duas bebidas mistas probióticas sabor goiaba e beterraba: BMAP (bebida mista à base de extrato de amendoim) e BMSP (à base de extrato de soja), que foram adicionadas de Lactobacillus rhamnosus GG. Avaliaram-se características sensoriais e microbiológicas das bebidas elaboradas e de uma bebida comercial a base de soja disponível no mercado (BSC). Verificou-se que, após o processamento, as bebidas BMAP, BMSP e a BSC apresentaram escores equivalentes a "gostei ligeiramente" e "gostei muito" para os atributos acidez, cor, sabor, aroma, textura e impressão global, e escores equivalentes a "talvez comprasse, talvez não comprasse" e "provavelmente compraria" na avaliação de intenção de compra, não havendo diferença das bebidas elaboradas para a comercial. Verificaram-se contagens de LGG superiores a 6,8 Log UFC. mL-1 nas bebidas. Todas as amostras estavam de acordo com os padrões microbiológicos exigidos pela legislação brasileira. As bebidas apresentam potencial de mercado e são consideradas um excelente veículo de LGG, além de uma nova opção de bebida funcional, não láctea, acessível à população.(AU)
Vegetable beverages have been studied as carriers of probiotic bacteria. The objective of this study was to elaborate two probiotic mixed beverages from guava and beet: BMAP (mixed beverage based on peanut extract) and BMSP (based on soy extract), which were added of Lactobacillus rhamnosus GG. Beverages from both matrices, without addition of probiotic, were denominated control (BMAC and BMSC). Sensory and microbiological characteristics of the elaborated beverages and a commercially available commercial soybean drink (BSC) were evaluated. It was verified that, after the processing, the BMAP, BMSP and BSC beverages presented "slightly liked" and "liked" scores for the attributes of acidity, color, flavor, aroma, texture and overall impression, and " maybe buy, maybe not buy "and" would probably buy "in the evaluation of the intention to buy, there being no difference of the beverages from to the commercial. LGG counts were above 6.8 Log UFC.mL-1 in the beverages. All samples were in accordance with the microbiological standards required by Brazilian legislation. The beverages present market potential and are considered a excellent vehicle of LGG and a new functional beverage option, not dairy, accessible to the population.
Subject(s)
Humans , Probiotics/administration & dosage , Functional Food , Fruit and Vegetable Juices/analysis , Fruit and Vegetable Juices/microbiology , Arachis , Soy Foods , Food AnalysisABSTRACT
Abstract Probiotics have provided benefits to general health, but they are still insufficient to dental health. Objective: This study aimed to evaluate milk supplemented with probiotic bacteria and standard milk, measured by levels of Streptococcus mutans (S. mutans) and Lactobacillus spp., in 3-4-year-old children after 9 months of intervention. Material and Methods: The study was a triple-blind, placebo-controlled, randomized trial. The sample was composed of 363 preschoolers attending five child development centers in Cali, Colombia. They were randomized to two groups: children in the intervention group drank 200 mL of milk with Lactobacillus rhamnosus 5x106 and Bifidobacteruim longum 3x106, and children in the control group drank 200 mL of standard milk. Interventions occurred on weekdays and information was gathered through scheduled clinical examination. The primary result was the number of colony forming units (CFU) of S. mutans and Lactobacillus spp. in the saliva. Secondary results were dental caries, rated by the International Caries Detection and Assessment System (ICDAS), dental plaque, pH, and salivary buffer capacity. Results: The proportion of S. mutans was lower in the intervention group compared with the control group after 9 months; however, the differences did not reach statistical significance (p=0.173); on the other hand, statistically significant differences between groups were found in the CFU/mL of Lactobacillus spp. (p=0.002). There was not statistically significant difference in the prevalence of dental caries for both groups (p=0.767). Differences between groups were found in the salivary buffering capacity (p=0.000); neither salivary pH nor dental plaque were significantly different. Conclusions: Regular consumption of milk containing probiotics bacteria reduced CFU/mL of Lactobacillus spp. and increased salivary buffering capacity at 9 months of consumption.
Subject(s)
Humans , Animals , Male , Female , Child, Preschool , Saliva/microbiology , Streptococcus mutans/isolation & purification , Probiotics/administration & dosage , Milk/chemistry , Lactobacillus/isolation & purification , Time Factors , Colony Count, Microbial , Reproducibility of Results , Treatment Outcome , Statistics, Nonparametric , Dental Caries/microbiology , Dental Caries/prevention & control , Dental Plaque/microbiology , Dental Plaque/prevention & control , Milk/microbiologyABSTRACT
ABSTRACT Objective: The aim of this double-blind, placebo-controlled and parallel- arm randomized clinical trial was to evaluate the effects of Lactobacillus rhamnosus SP1-containing probiotic sachet and azithromycin tablets as an adjunct to nonsurgical therapy in clinical parameters and in presence and levels of Tannerella forsythia, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans. Material and Methods: Forty-seven systemically healthy volunteers with chronic periodontitis were recruited and monitored clinically and microbiologically at baseline for 3, 6 and 9 months after therapy. Subgingival plaque samples were collected from four periodontal sites with clinical attachment level ≥1 mm, probing pocket depth ≥4 mm and bleeding on probing, one site in each quadrant. Samples were cultivated and processed using the PCR technique. Patients received nonsurgical therapy including scaling and root planing (SRP) and were randomly assigned to a probiotic (n=16), antibiotic (n = 16) or placebo (n = 15) group. L. rhamnosus SP1 was taken once a day for 3 months. Azithromycin 500mg was taken once a day for 5 days. Results: All groups showed improvements in clinical and microbiological parameters at all time points evaluated. Probiotic and antibiotic groups showed greater reductions in cultivable microbiota compared with baseline. The placebo group showed greater reduction in number of subjects with P. gingivalis compared with baseline. However, there were no significant differences between groups. Conclusions: The adjunctive use of L. rhamnosus SP1 sachets and azithromycin during initial therapy resulted in similar clinical and microbiological improvements compared with the placebo group.
Subject(s)
Humans , Male , Female , Adult , Azithromycin/therapeutic use , Probiotics/therapeutic use , Lacticaseibacillus rhamnosus/chemistry , Chronic Periodontitis/drug therapy , Anti-Bacterial Agents/therapeutic use , Time Factors , Colony Count, Microbial , Placebo Effect , Periodontal Index , Polymerase Chain Reaction , Double-Blind Method , Analysis of Variance , Dental Scaling/methods , Treatment Outcome , Aggregatibacter actinomycetemcomitans/isolation & purification , Aggregatibacter actinomycetemcomitans/drug effects , Azithromycin/pharmacology , Porphyromonas gingivalis/isolation & purification , Porphyromonas gingivalis/drug effects , Statistics, Nonparametric , Probiotics/pharmacology , Dental Plaque/microbiology , Dental Plaque/drug therapy , Tannerella forsythia/isolation & purification , Tannerella forsythia/drug effects , Middle Aged , Anti-Bacterial Agents/pharmacologyABSTRACT
La lactancia materna es un excelente factor protector y una forma inigualable de facilitar el alimento ideal para el crecimiento y desarrollo saludable. Es imprescindible su recomenda-ción exclusiva durante los primeros 6 meses de vida y de ser posible continuar con la lactancia materna durante la alimentación complemen-taria hasta los 2 años de edad; solo se debe recurrir a fórmulas especiales cuando la madre no pueda amamantar. Para estos casos se dispone de varias fórmulas hidrolizadas, soja y elementales.Las fórmulas hidrolizadas pueden ser extensa o parcialmente hidrolizadas, y ser séricas o de caseína. Las fórmulas extensamente hidroliza-das, han sido sometidas a ensayos clínicos donde se comprueba su hipoalergenicidad al eliminar los síntomas de la Alergia a la Proteína de la Leche de Vaca (APLV) luego de su inicio. Estudios recientes demuestran que la adición de Lactobacillusr hamnosus (LGG) a una fórmu-la de caseína extensamente hidrolizada acelera la adquisición de tolerancia en estos niños en comparación con los pacientes que recibieron fórmula sin adición.La fórmula de soja, aunque no es hipoalergéni-ca, se puede emplear para tratar la APLV, pero no antes de los 6 meses. No se pueden emplear como tratamiento de APLV fórmulas parcial-mente hidrolizadas, ni leche de otros rumian-tes, como oveja o cabra. En pacientes con altos niveles de sensibilización o con antecedente de reacción ana láctica, se recomienda la administración de fórmula elemental. El objeti-vo de la presente revisión es dar a conocer el manejo y uso racional de las fórmulas hidroliza-das y elementales en niños con APLV y así evitar el uso indiscriminado de estas en niños con trastornos funcionales...(AU)
Subject(s)
Humans , Infant, Newborn , Infant , Protein Hydrolysates/therapeutic use , Breast Feeding/methods , Milk Hypersensitivity/complications , Whey Proteins/adverse effectsABSTRACT
Aims: Five Lactobacillus rhamnosus strains (UBU03, UBU06, UBU09, UBU34 and UBU37) with good in vitro probiotic properties, isolated from breast-fed infants, were evaluated for in vitro adhesion, competitive adhesion and immunomodulatory properties. Knowledge of such properties is important when considering specific circumstances when these strains might be used clinically. Methodology and results: The Caco-2 cell line was used for adhesion assays and for competitive adhesion assays against Escherichia coli O157:H7. Lactobacillus rhamnosus GG was used as the reference strain for adhesion assays. The immunomodulatory activities of the five strains were evaluated by determining the levels of the inflammatory cytokines IL-6, IL-12 and TNF-α, and of the immunoregulatory cytokine IL-10, produced by bacterial-activated THP-1 cells after 6, 12 and 24 h of stimulation. In the cell-adhesion assays, all five strains showed high adhesion properties. For UBU09, UBU34 and UBU37, adhesive capacity was higher than that of the reference strain. All strains except UBU03 showed the ability to inhibit adhesion of E. coli O157:H7 to Caco-2 cells. All strains induced IL-6 production but not IL-12 production. UBU03 and UBU09 could induce only one cytokine IL-6. UBU06 and UBU34 could each induce two (IL-6/IL-10 and IL-6/TNF-α, respectively). UBU37 could induce three cytokines (IL-6/TNF-α /IL-10). Conclusion, significance and impact of study: These five probiotic L. rhamnosus strains with high adhesion properties and with different in vitro cytokine induction profiles should be investigated further in different immunological conditions to identify appropriate circumstances for their clinical use.
ABSTRACT
To describe a novel particles surface display system which is consisted of gram-positive enhancer matrix (GEM) particles and anchor proteins for bacteria-like particles vaccines, we treated Lactobacillus rhamnosus GG bacteria with 10% heated-TCA for preparing GEM particles, and then identified the harvested GEM particles by electron microscopy, RT-PCR and SDS-PAGE. Meanwhile, Escherichia coli was induced to express hybrid proteins PA3-EGFP and P60-EGFP, and GEM particles were incubated with them. Then binding of anchor proteins were determined by Western blotting, transmission electron microscopy, fluorescence microscopy and spectrofluorometry. GEM particles preserved original size and shape, and proteins and DNA contents of GEM particles were released substantially. The two anchor proteins both had efficiently immobilized on the surface of GEM. GEM particles that were bounded by anchor proteins were brushy. The fluorescence of GEM particles anchoring PA3 was slightly brighter than P60, but the difference was not significant (P>0.05). GEM particles prepared from L. rhamnosus GG have a good binding efficiency with anchor proteins PA3-EGFP and P60-EGFP. Therefore, this novel foreign protein surface display system could be used for bacteria-like particle vaccines.